THE chief executive of listed medical technology company Medigard is in the US on a deal sealing mission for the company’s retractable syringe and blood collection device.
Peter Emery is aiming to lock down both a distributor and a manufacturer for the product.
“We’re locking the doors and putting all of our focus into securing these deals,” says Emery.
The company announced in December that it had entered a heads of agreement with a US medical device manufacturer.
“It has taken a while, but we are confident we have identified a good group of people. The timing now is critical. It is frustrating being in (the) medical devices industry, but people are very happy with our products and we continue to receive good feed back.”
Chairman Don Channer and director Peter Clark are majority shareholders of Medigard, owning 50 per cent between them.
MEDIGARD IN US TO SEAL DEAL
8 June 2010
Latest News
Equity Trustees abandons superannuation management in fallout from First Guardian collapse
EQT Holdings (ASX: EQT) has announced its Equity Trustees subsidiar...
Credit Corp abandons $385m Humm Group takeover bid, bringing seven-month battle to a close
Debt collections group Credit Corp (ASX: CCP) has walked away...
Green360 expands concrete platform with silica fume replacement as coal plant closures bite
Green cement materials company Green360 Technologies (ASX: GT3) has...
Metcash profit dips as resilient food earnings offset by weaker growth in liquor and hardware sales
Wholesale distribution and retail group Metcash's (ASX: MT...
SavvyWise valuation hits $27.5m as accountants back AI tax platform’s $1.56m crowdfunding raise
Perth-based AI tax research platform SavvyWise has closed a $1.56 m...
Partner Content
For most Australian homeowners, the house gets the attention and the land gets taken fo...
Ventures & VisionariesAdvertisement

)

